Health Ministry issues advisory of potential thromboembolic incidents
Adverse Event Following Immunisation (AEFI) data in India showed that there is a minuscule but definitive risk of thromboembolic events after the AstraZeneca-Oxford vaccine (Covishield in India).
A statement issued by the Health Ministry on Monday noted that the reporting rate of these events in India is around 0.61/million doses, which is much lower than the four cases/million reported by UK’s regulator Medical and Health Regulatory Authority (MHRA). Germany has reported 10 events per million doses.
There were no potential thromboembolic events reported following administration of Covaxin vaccine. Bleeding and clotting cases following COVID vaccination in India are minuscule and in line with the expected number of diagnoses of these conditions in the country, a report submitted by the National AEFI to the Health Ministry noted.
Bleeding, clotting events following COVID-19 vaccination minuscule in India: Government report
The Union Health Ministry is separately issuing advisories to Healthcare Workers and Vaccine Beneficiaries to encourage people to be aware of suspected thromboembolic symptoms occurring within 20 days after receiving any COVID-19 vaccine
The National Adverse Event Following Immunization (AEFI) Committee in its report submitted to the Union Health Ministry said that bleeding and clotting cases following COVID vaccination in India are minuscule and in line with the expected number of diagnoses of these conditions in the country. According to a statement issued on Monday by the Ministry of Health and Family Welfare, alerts have been raised in some countries on post-vaccination embolic and thrombotic events on March 11 particularly with the AstraZeneca-Oxford vaccine (COVISHIELD in India).
The National Adverse Event Following Immunisation committee has completed an in-depth case review of 498 serious and severe events, of which 26 cases have been reported to be potential thromboembolic.
Bleeding, clotting events after vaccination minuscule in India: Report
By IANS |
0 Views
Since the Covid-19 vaccination drive was initiated, more than 23,000 adverse events were reported through the CoWIN platform from 684 of the 753 districts of the country. Image Source: IANS News
New Delhi, May 17 : Incidents of bleeding or clotting following Covid-19 vaccination in India are minuscule and in line with the expected number of diagnoses of these conditions in the country, according to a report submitted by the National AEFI (Adverse Event Following Immunization) Committee to the Ministry of Health and Family Welfare (MoHFW).
Alerts were raised in some countries on post-vaccination embolic and thrombotic events on March 11 this year, particularly with the AstraZeneca-Oxford vaccine (Covishield in India), said the report.